Navigation Links
Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
Date:10/8/2008

Review Zanolimumab Program to be Discontinued and Headcount to be Reduced Summary: Genmab Announces the Results of its Portfolio Review; Zanolimumab

Program to be Discontinued and the Company Will Reduce the Number of

Employees

COPENHAGEN, October 8 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that it is discontinuing development of zanolimumab (HuMax-CD4(R)). In addition, as a result of a portfolio review and assessment of the organization, Genmab is reducing its headcount by 101 positions.

As the company approaches potential commercialization, the need to establish a sustainable level of R&D investment is a key priority. Genmab has conducted a review of its portfolio and organization to establish priorities that will build the greatest potential value. The company will sharpen its focus on cancer therapeutics and a less broad, but higher potential portfolio.

Zanolimumab is currently in a Phase III pivotal study to treat cutaneous T-cell lymphoma (CTCL). As Genmab has previously indicated, patient recruitment into the zanolimumab pivotal study has been slow which the company believes is due to the relatively small market potential in CTCL, the introduction of a new CTCL therapeutic to the market and numerous competing clinical trials. In the light of these issues, Genmab considers that the significant investment required to take the product through to approval is no longer a good use of its resources.

Genmab will also aim to out-license three of its early stage development programs that fall outside the focus area: HuMax-HepC(TM), HuMax-IL8(TM) and HuMax-TAC(TM).

In addition, Genmab will wind down the zalutumumab (HuMax-EGFr(TM)) early stage studies in colorectal and lung cancer. This decision is based on new information about the role of K-RAS mutations and appropriate therapeutic regimens. Genmab will continue its development of two Phase III and two earlier stage
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genmab Announces Upcoming Ofatumumab Studies
2. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
3. Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
4. Genmab Reaches Milestone in Ofatumumab Collaboration
5. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
6. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
7. Genmab Announces Updates on Phase III Cancer Studies
8. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
9. Bionomics Achieves US$1 Million Milestone Payment from Genmab
10. DAHANCA Initiates Head and Neck Cancer Study With Genmabs HuMax-EGFr
11. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical care ... technology to help fight deadly inflammation in critically-ill ... today announced the appointment of Dr. Gregory ... Senior Vice President of Clinical Development, effective January ... Russo is an accomplished pediatric cardiothoracic surgeon ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... Jan. 17, 2012 To address the growing need ... with the automation of routine clinical laboratory assays, ... Tecan Group (SIX Swiss Exchange: TECN) today entered into ... handling platform with Waters® ACQUITY® TQD liquid ...
... RIVER EDGE, N.J., Jan. 17, 2012  Nephros, Inc. (OTC ... developing and marketing filtration products for therapeutic applications, infection ... 16, 2012, Nephros received a payment of euro 750,000 ... Under the terms of the license agreement ...
Cached Medicine Technology:Waters and Tecan Sign Agreement for Clinical Assay Platform 2Waters and Tecan Sign Agreement for Clinical Assay Platform 3Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 2Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 3Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 4
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Thousands ... to move forward in a number of multidistrict litigations ... West Virginia, Bernstein Liebhard LLP reports. According to an ... scheduled to convene a Joint Status Conference in all ... a.m. Parties have been directed to submit a proposed ...
(Date:12/25/2014)... 2014 Residents at Abernethy ... showed their generous spirit by providing holiday gifts ... Parenting Network- Grandparents Raising Grandchildren program. , Following ... the largest Christmas tree on the campus of ... residents of the Abernethy Village Association (AVA). Each ...
(Date:12/24/2014)... 2014 AlignLife of Wauwatosa loves ... certain items. During the holiday season, AlignLife looks forward to ... toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings ... knowing that we are able to give kids toys for ... been for the generosity of our patients." , The 70 ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... The Malaria in Pregnancy Consortium, led by the Liverpool ... by the European and Developing Countries Clinical Trials Partnership ... of an antimalarial drug given to prevent malaria in ... a major cause of severe maternal anaemia and preventable ...
... down Silos and Benefiting from Paperless Lab MILFORD, ... Corporation (NYSE: WAT ) and LabVantage ... to integrate laboratory software for improved efficiency and ... existing common customers, Waters(R) and LabVantage(R) have already ...
... A new analysis by Avalere Health found that ... -- a full 10% higher than amounts reported in ... not include spending on assisted living, a key component ... California-based SCAN Foundation, found that individuals and their families ...
... Leader BioFortis wins another award for its ... and institutional clients worldwide for translational research, ... March 5 /PRNewswire/ -- BioFortis, ... solutions used by pharmaceutical and institutional clients, ...
... the Basics: Healthy Living Web Source Offers Tips on Fitness ... & Spa ExperienceWESTCHESTER, Ill., March 5 Research shows that ... fall off the wagon by Valentine,s Day(1). If this ... in the first place? Old London, the makers of ...
... Philadelphia, 5 March 2009 The new medical subspecialty ... the way in providing technically advanced yet cost-effective care ... in the March issue of the Journal of ... the Heart Failure Society of America (HFSA) and the ...
Cached Medicine News:Health News:LSTM and MiP Consortium awarded further $4.5 million 2Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 2Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 3Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 4Health News:Almost 30% of Long-Term Care is Financed Out-of-Pocket, Report Finds 2Health News:BioFortis Wins Best Product Award in Discovery Informatics at the 2009 Molecular Medicine Tri-Conference 2Health News:Samantha Harris Launches 'A Toast for Everyday Health' 2Health News:Samantha Harris Launches 'A Toast for Everyday Health' 3Health News:Samantha Harris Launches 'A Toast for Everyday Health' 4Health News:New specialty to focus on advanced heart failure and heart transplantation 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: